Article
Behavioral Sciences
Mary Seeman
Summary: The review examines the potential role of intestinal organisms in response/non-response to antipsychotics, highlighting that current research in this area is mostly theoretical but showing increasing evidence from animal experiments and clinical trials on the impact of gut bacteria on drug response.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Review
Oncology
Jia-Ting Huang, Yu-Qin Mao
Summary: Abnormal metabolic alterations of cancer cells and the host play crucial roles in tumor occurrence and development. The gut microbiota and their metabolites have been found to have significant influence on tumor formation, prognosis, and treatment. Manipulating the structure and metabolites of the gut microbiota can provide protective effects against tumors.
FRONTIERS IN ONCOLOGY
(2022)
Review
Chemistry, Medicinal
Sarah J. Skuli, Safwan Alomari, Hallie Gaitsch, A'ishah Bakayoko, Nicolas Skuli, Betty M. Tyler
Summary: Metformin, as a drug, not only reduces the risk of cancer in type 2 diabetics but also inhibits cell growth in various cancers. However, its mechanism of action in cancer cells and its effect on cancer metabolism are still unclear.
Review
Pathology
Joseph C. Sedlak, Omer H. Yilmaz, Jatin Roper
Summary: Reprogrammed metabolism is a key characteristic of colorectal cancer (CRC). Intestinal stem cells (ISCs), the main origin cells for CRC, need to adapt their metabolism in response to the unique microenvironment, including interactions with various cells and dietary factors. Modifiable risk factors related to the environment, such as diet, play an important role in CRC pathogenesis. Understanding the mechanistic links between environmental factors, metabolic adaptations, and the tumor microenvironment has potential for improved CRC prevention and treatment.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE
(2023)
Review
Gastroenterology & Hepatology
Georgina R. Jones, Mark P. Molloy
Summary: Metformin, widely used in treating T2DM, has shown potential in reducing CRC risk, but the molecular mechanisms behind its gastrointestinal anti-cancer properties are complex and not well understood. Interaction between metformin, gut microbiota, and colonic epithelial mucosa may play a role in its protection against CRC.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Review
Oncology
Elisabet Cuyas, Sara Verdura, Begona Martin-Castillo, Javier A. Menendez
Summary: Research suggests that the anti-diabetic drug metformin can modulate the chromatin state of cancer cells, affecting their function. Metformin has the ability to target global metabolic pathways or specific metabolic enzymes, regulating the production of chromatin-modifying metabolites, and indirectly or directly adjusting the activation status of chromatin-modifying enzymes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Chun-Jung Chen, Chih-Cheng Wu, Cheng-Yi Chang, Jian-Ri Li, Yen-Chuan Ou, Wen-Ying Chen, Su-Lan Liao, Jiaan-Der Wang
Summary: The study found that metformin can alleviate tumor growth caused by high-fat diet, inhibit inflammation, and may be a potential treatment for obesity-related cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Maxime Parisotto, Nhung Vuong-Robillard, Paloma Kalegari, Thulaj Meharwade, Loick Joumier, Sebastian Igelmann, Veronique Bourdeau, Marie-Camille Rowell, Michael Pollak, Mohan Malleshaiah, Andreea Schmitzer, Gerardo Ferbeyre
Summary: The use of metformin as a single antitumor agent has been disappointing, but combining it with the NAD biosynthesis inhibitor FK866 has shown superior antitumor activity. This study reveals the mechanism of metformin's antitumor actions and suggests that targeting mitochondria and NAD biosynthesis can lead to effective antitumor therapies.
Review
Chemistry, Medicinal
Izabela Szymczak-Pajor, Sylwia Wenclewska, Agnieszka Sliwinska
Summary: Metformin, a first-line drug for T2DM treatment, influences metabolism through various mechanisms. It suppresses hepatic glucose production and intestinal lipid secretion, while enhancing fatty acid oxidation in adipose tissue and muscles. Additionally, metformin improves systemic insulin sensitivity by altering gut microbiota composition, maintaining intestinal barrier integrity, and alleviating low-grade inflammation.
Article
Oncology
Croi E. Buckley, Rebecca M. O'Brien, Timothy S. Nugent, Noel E. Donlon, Fiona O'Connell, John V. Reynolds, Adnan Hafeez, Diarmuid S. O'Riordain, Robert A. Hannon, Paul Neary, Reza Kalbassi, Brian J. Mehigan, Paul H. McCormick, Cara Dunne, Michael E. Kelly, John O. Larkin, Jacintha O'Sullivan, Niamh Lynam-Lennon
Summary: Resistance to neoadjuvant chemoradiation therapy is a challenge in rectal cancer management. This study investigated the impact of metformin on radiosensitivity in colorectal cancer cells and identified potential mechanisms. The results showed that metformin treatment significantly increased radiosensitivity and altered energy metabolism, mitochondrial function, cell cycle, cell death and antioxidant levels. Furthermore, metformin inhibited oxidative phosphorylation and glycolysis in rectal cancer tissue without affecting non-cancerous tissue, suggesting its potential as an anti-metabolic radiosensitiser.
FRONTIERS IN ONCOLOGY
(2023)
Article
Food Science & Technology
Shuyuan Cao, Shengjie Hu, Ping Jiang, Zhan Zhang, Lei Li, Qian Wu
Summary: Sulforaphane (SFN) has a wide range of antitumor activities by inhibiting breast cancer cell proliferation and affecting metabolome and microbiome.
FOOD SCIENCE & NUTRITION
(2023)
Article
Polymer Science
Anindita De, Ashish Wadhwani, Parikshit Sauraj, Parikshit Roychowdhury, Ji Hee Kang, Young Tag Ko, Gowthamarajan Kuppusamy
Summary: The Warburg effect offers a new approach to cancer metabolism treatment. GLUT1 overexpression, AMPK activation, and mTOR downregulation are identified as biomarkers of abnormal cancer cell metabolism. A combination therapy of WZB117 (a GLUT1 inhibitor), OCMC (O-carboxymethyl-chitosan), and MET is proposed for simultaneous targeting of GLUT1 and mTOR to alter breast cancer metabolism. The strategy overcomes the limitations of MET monotherapy by synergistically targeting mTOR and BCL2.
Article
Immunology
Ylaine Gerardin, Sonia Timberlake, Jessica R. Allegretti, Mark B. Smith, Zain Kassam
Summary: The transfer of live gut microbes may revolutionize the treatment of various diseases, with fecal microbiota transplantation showing early success in certain infections. The development of microbiome drugs is now being driven by these clinical advances, although challenges remain in terms of safety, consistency, and delivery.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Pharmacology & Pharmacy
Sri Nitya Reddy Induri, Payalben Kansara, Scott C. Thomas, Fangxi Xu, Deepak Saxena, Xin Li
Summary: Metformin is widely used for treating type 2 diabetes and may promote healthy aging. The gut microbiome could play a role in the efficacy of metformin as its concentration is higher in the gut. Understanding the mechanisms of metformin in promoting a healthy gut microbiome and aging requires a systems-level approach.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Barbara Costa, Nuno Vale
Summary: Breast cancer is a heterogeneous disease with four major molecular subtypes, which have different risk profiles and treatment methods. Early detection improves treatment prospects, but some early-stage patients still face metastasis or resistance to chemotherapy. Immunotherapy is a promising option, but only a small subset of patients respond well in the long term. Current strategies focus on histopathological examination and molecular diagnosis, neglecting the tumor microenvironment and microbiome. Utilizing pharmacogenomics and pharmacomicrobiomics can identify potential biomarkers for real-time therapy guidance and monitoring, considering drug metabolism and its relationship with the microbiome.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Microbiology
Ener C. Dinleyici, Daniel Martinez-Martinez, Ates Kara, Adem Karbuz, Nazan Dalgic, Ozge Metin, Ahmet S. Yazar, Sirin Guven, Zafer Kurugol, Ozden Turel, Mehmet Kucukkoc, Olcay Yasa, Makbule Eren, Metehan Ozen, Jose Manuel Marti, Carlos P. Garay, Yvan Vandenplas, Andres Moya
FRONTIERS IN MICROBIOLOGY
(2018)
Article
Cell Biology
Alexandre Benedetto, Timothee Bambade, Catherine Au, Jennifer M. A. Tullet, Jennifer Monkhouse, Hairuo Dang, Kalina Cetnar, Filipe Cabreiro, Brian Chan, David Gems
Article
Biochemistry & Molecular Biology
Rosina Pryor, Povilas Norvaisas, Georgios Marinos, Lena Best, Louise B. Thingholm, Leonor M. Quintaneiro, Wouter De Haes, Daniela Esser, Silvio Waschina, Celia Lujan, Reuben L. Smith, Timothy A. Scott, Daniel Martinez-Martinez, Orla Woodward, Kevin Bryson, Matthias Laudes, Wolfgang Lieb, Riekelt H. Houtkooper, Andre Franke, Liesbet Temmerman, Ivana Bjedov, Helena M. Cocheme, Christoph Kaleta, Filipe Cabreiro
Article
Biochemical Research Methods
Jack W. Rutter, Tanel Ozdemir, Evgeniy R. Galimov, Leonor M. Quintaneiro, Luca Rosa, Geraint M. Thomas, Filipe Cabreiro, Chris P. Barnes
ACS SYNTHETIC BIOLOGY
(2019)
Article
Multidisciplinary Sciences
Clara L. Essmann, Daniel Martinez-Martinez, Rosina Pryor, Kit-Yi Leung, Kalaivani Bala Krishnan, Prudence Pokway Lui, Nicholas D. E. Greene, Andre E. X. Brown, Vijay M. Pawar, Mandayam A. Srinivasan, Filipe Cabreiro
NATURE COMMUNICATIONS
(2020)
Article
Cell Biology
Garik V. Mkrtchyan, Kotb Abdelmohsen, Penelope Andreux, Ieva Bagdonaite, Nir Barzilai, Soren Brunak, Filipe Cabreiro, Rafael de Cabo, Judith Campisi, Ana Maria Cuervo, Marco Demaria, Collin Y. Ewald, Evandro Fei Fang, Richard Faragher, Luigi Ferrucci, Adam Freund, Carlos G. Silva-Garcia, Anastasia Georgievskaya, Vadim N. Gladyshev, David J. Glass, Vera Gorbunova, Aubrey de Grey, Wei-Wu He, Jan Hoeijmakers, Eva Hoffmann, Steve Horvath, Riekelt H. Houtkooper, Majken K. Jensen, Martin Borch Jensen, Alice Kane, Moustapha Kassem, Peter de Keizer, Brian Kennedy, Gerard Karsenty, Dudley W. Lamming, Kai-Fu Lee, Nanna MacAulay, Polina Mamoshina, Jim Mellon, Marte Molenaars, Alexey Moskalev, Andreas Mund, Laura Niedernhofer, Brenna Osborne, Heidi H. Pak, Andrey Parkhitko, Nuno Raimundo, Thomas A. Rando, Lene Juel Rasmussen, Carolina Reis, Christian G. Riedel, Anais Franco-Romero, Bjoern Schumacher, David A. Sinclair, Yousin Suh, Pam R. Taub, Debra Toiber, Jonas T. Treebak, Dario Riccardo Valenzano, Eric Verdin, Jan Vijg, Sergey Young, Lei Zhang, Daniela Bakula, Alex Zhavoronkov, Morten Scheibye-Knudsen
Article
Genetics & Heredity
Ivana Bjedov, Helena M. Cocheme, Andrea Foley, Daniela Wieser, Nathaniel S. Woodling, Jorge Ivan Castillo-Quan, Povilas Norvaisas, Celia Lujan, Jenny Regan, Janne M. Toivonen, Michael P. Murphy, Janet Thornton, Kerri J. Kinghorn, Thomas P. Neufeld, Filipe Cabreiro, Linda Partridge
Article
Veterinary Sciences
Cassandra Backes, Daniel Martinez-Martinez, Filipe Cabreiro
Summary: Microbes play a crucial role in shaping interactions between hosts and their environment. The nematode Caenorhabditis elegans is a powerful tool for studying microbe-host interactions, utilizing genetic tools and in-depth phenotyping to uncover key effectors in this complex relationship. Research using C. elegans as a model system highlights innovative methodologies and key findings in understanding host-microbe interactions.
Article
Cell Biology
Victoria Eugenia Martinez-Miguel, Celia Lujan, Tristan Espie-Caullet, Daniel Martinez-Martinez, Saul Moore, Cassandra Backes, Suam Gonzalez, Evgeniy R. Galimov, Andre E. X. Brown, Mario Halic, Kazunori Tomita, Charalampos Rallis, Tobias von der Haar, Filipe Cabreiro, Ivana Bjedov
Summary: The loss of proteostasis is a fundamental process driving aging, and the accuracy of translation significantly affects proteostasis. A rare amino acid substitution found in certain hyperthermophilic archaea, when introduced into other organisms, improves translation accuracy, heat shock resistance, and longevity. Anti-aging drugs such as rapamycin, Torin1, and trametinib reduce translation errors and extend organismal longevity, particularly in mutants with high translation accuracy due to this unique substitution in the RPS23 protein.
Article
Multidisciplinary Sciences
Martina Kluenemann, Sergej Andrejev, Sonja Blasche, Andre Mateus, Prasad Phapale, Saravanan Devendran, Johanna Vappiani, Bernd Simon, Timothy A. Scott, Eleni Kafkia, Dimitrios Konstantinidis, Katharina Zirngibl, Eleonora Mastrorilli, Manuel Banzhaf, Marie-Therese Mackmull, Felix Hoevelmann, Leo Nesme, Ana Rita Brochado, Lisa Maier, Thomas Bock, Vinita Periwal, Manjeet Kumar, Yongkyu Kim, Melanie Tramontano, Carsten Schultz, Martin Beck, Janosch Hennig, Michael Zimmermann, Daniel C. Sevin, Filipe Cabreiro, Mikhail M. Savitski, Peer Bork, Athanasios Typas, Kiran R. Patil
Summary: Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs by bioaccumulating them intracellularly without chemically modifying them. This process can alter drug availability and bacterial metabolism, with implications for microbiota composition, pharmacokinetics, side effects and drug responses, potentially in an individualized manner.
Article
Genetics & Heredity
Yi Liu, Daniel Martinez-Martinez, Clara L. Essmann, Melissa R. Cruz, Filipe Cabreiro, Danielle A. Garsin
Summary: SKPO-1, a peroxidase in C. elegans, plays a role in pathogen sensitivity and cuticle development. Its loss results in dysregulation of genes related to cuticle development and failure to upregulate guanylyl cyclases involved in environmental sensing. These findings provide insights into the phenotypes associated with loss of SKPO-1 function.
G3-GENES GENOMES GENETICS
(2021)
